Jeffrey Betcher
Overview
Explore the profile of Jeffrey Betcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shah V, Spence A, Bartels T, Betcher J, Soefje S
Am J Health Syst Pharm
. 2021 Dec;
79(8):676-682.
PMID: 34940791
Purpose: To decrease drug waste and cost by implementing automated chemotherapy dose rounding rules in the electronic health record (EHR). Dose rounding of chemotherapy is a recognized method for reducing...
2.
Bhella S, Majhail N, Betcher J, Costa L, Daly A, Dandoy C, et al.
Biol Blood Marrow Transplant
. 2018 Jan;
24(5):909-913.
PMID: 29360515
Choosing Wisely encourages dialogue about reducing unnecessary procedures, tests, or treatments in healthcare. The American Society for Blood and Marrow Transplantation (ASBMT) and Canadian Blood and Marrow Transplant Group (CBMTG)...
3.
Bryk A, Koontz S, Mayor J, Betcher J, Tombleson R, Bookout R, et al.
J Oncol Pharm Pract
. 2017 Dec;
25(3):558-566.
PMID: 29207938
Background: Current workforce shortages within the hematopoietic stem cell transplant field necessitate capitalizing on the role of oncology-trained pharmacists. Working within an agreed-upon protocol, pharmacists are able to expand patient...
4.
Mailman J, Betcher J, Semchuk W
Can J Hosp Pharm
. 2017 Nov;
70(5):395-396.
PMID: 29109584
No abstract available.
5.
Betcher J, Dow E, Khera N
Curr Hematol Malig Rep
. 2016 Apr;
11(4):288-94.
PMID: 27086140
Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients...
6.
Betcher J, Van Ryan V, Mikhael J
J Infus Nurs
. 2015 Sep;
38(5):341-8.
PMID: 26339940
Chronic anemia develops over a course of weeks to months and is usually mild to moderate in nature. It is important to understand the etiology of the reduced number of...
7.
Cherington C, Slack J, Leis J, Adams R, Reeder C, Mikhael J, et al.
Leuk Res
. 2012 May;
36(9):1147-51.
PMID: 22578777
The prognosis for patients with Philadelphia-negative myeloproliferative neoplasms (MPN) who evolve into acute myeloid leukemia (AML) or blast phase (MPN-BP) is extremely poor. Although allogeneic stem cell transplantation (allo-SCT) is...
8.
Hastings D, Patel B, Torloni A, Mookadam F, Betcher J, Moss A, et al.
J Clin Apher
. 2009 Jan;
24(1):28-31.
PMID: 19156754
Rituximab (Rituxan), a genetically engineered chimeric murine and human IgG1 monoclonal antibody directed against CD20 antigen, is an emerging drug used for a wide spectrum of disease processes and found...